Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

MoonLake Immunotherapeutics logo
$37.21 -0.85 (-2.23%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$37.12 -0.09 (-0.26%)
As of 04/4/2025 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

Key Stats

Today's Range
$35.93
$38.56
50-Day Range
$36.35
$47.12
52-Week Range
$35.39
$58.26
Volume
484,875 shs
Average Volume
342,020 shs
Market Capitalization
$2.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.50
Consensus Rating
Buy

Company Overview

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Remove Ads

MoonLake Immunotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

MLTX MarketRank™: 

MoonLake Immunotherapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 647th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MoonLake Immunotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    MoonLake Immunotherapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about MoonLake Immunotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.79) to ($2.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MoonLake Immunotherapeutics is -28.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MoonLake Immunotherapeutics is -28.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MoonLake Immunotherapeutics has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about MoonLake Immunotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.72% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently decreased by 2.69%, indicating that investor sentiment is improving.
  • Dividend Yield

    MoonLake Immunotherapeutics does not currently pay a dividend.

  • Dividend Growth

    MoonLake Immunotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.72% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently decreased by 2.69%, indicating that investor sentiment is improving.
  • News Sentiment

    MoonLake Immunotherapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for MoonLake Immunotherapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    1 people have searched for MLTX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MoonLake Immunotherapeutics' insider trading history.
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLTX Stock News Headlines

MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
See More Headlines

MLTX Stock Analysis - Frequently Asked Questions

MoonLake Immunotherapeutics' stock was trading at $54.15 on January 1st, 2025. Since then, MLTX shares have decreased by 31.3% and is now trading at $37.21.
View the best growth stocks for 2025 here
.

MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its quarterly earnings data on Wednesday, February, 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.09.

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET).

Company Calendar

Last Earnings
2/26/2025
Today
4/04/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MLTX
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$80.50
High Stock Price Target
$104.00
Low Stock Price Target
$66.00
Potential Upside/Downside
+116.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-36,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$8.15 per share
Price / Book
4.57

Miscellaneous

Free Float
56,224,000
Market Cap
$2.38 billion
Optionable
Optionable
Beta
1.31
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:MLTX) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners